BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.40), $0.27 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $3.26 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.